{"schema_version":"secwatch.filing_event.v1","accession":"0001005286-23-000118","form_type":"8-K","ticker":"LFCR","cik":"0001005286","company_name":"LIFECORE BIOMEDICAL, INC. DE","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.811622+00:00","generated_at":"2026-06-09T03:58:51.553672+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Lifecore Biomedical restating FY21, FY22 financials for errors in interest, inventory, and divestitures","bullets":["Audit committee concludes prior financials for FY21, FY22, and interim periods 2020-2023 should no longer be relied upon.","Errors involve capitalized interest calculation, inventory valuation, and adjustments related to former Curation Foods segment.","Material weaknesses in internal control over financial reporting identified as of May 29, 2022.","Restatement expected to impact FY23 earnings release; company expects no adverse effect on operations or liquidity."],"urls":{"canonical":"https://secwatch.observer/filing/0001005286-23-000118","json":"https://secwatch.observer/filing/0001005286-23-000118.json","markdown":"https://secwatch.observer/filing/0001005286-23-000118.md","text":"https://secwatch.observer/filing/0001005286-23-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000118/0001005286-23-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000118/lndc-20231030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:58:51.553672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc5115b8d888e52972fafdff5db366c85b7bfcc7","claim":"LIFECORE BIOMEDICAL, INC. DE reported that prior financial statements should not be relied upon.","evidence_excerpt":"lidated results as of and for the fourth quarter and fiscal year ended May 28, 2023 (“FY23”) and furnished on Form 8-K with the SEC on August 31, 2023 (the “Earnings Release”) (collectively, the “Non-Reliance Periods”), should no longer be relied upon. This determination resulted from the Company’s identification of errors in the Non-Reliance Periods related to certain adjustments as more particularly described below, involving the calculation of capitalized interest, valuation of inventories, and certain adjustments related to previously divested businesses contained in the Non-Reliance Periods. In addition, the Company expects to correct certain items that were previously identified and concluded as immaterial, individually and in the aggregate, to the financial statements for the Non-Reliance Periods. The Company has assessed the materiality of these errors in accordance with the U.S.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005286/000100528623000118/0001005286-23-000118-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}